Eight to twelve weeks at a real dose.
Sections
Eight to twelve weeks at a real dose. That’s the honest answer, and almost nobody hears it before they start, which is most of why patients quit at week three when the side effects are at their peak and the benefit hasn’t shown up yet. The “four to six weeks” answer your prescriber probably gave you is technically right for partial response in the average patient, but full response, the kind that actually puts your life back together, is usually further out than that, and the path from week one to week twelve does not look like a tidy upward slope.
I’m going to walk you through what week one through week twelve actually feels like, in order, with the understanding that any prescriber who tells you “give it a month, you’ll feel great” is shading the timeline to manage your expectations down. The actual timeline is longer and bumpier than that, and going in knowing what to expect is most of the work of not bailing out three weeks in.
Week one
You start the drug. You feel the side effects. Nausea, sometimes some sleep weirdness, sometimes a kind of jittery uptick in anxiety that makes you wonder whether the drug is actually making you worse. It isn’t. It’s the side effect profile of the ramp-up showing up first, because the side effect profile shows up in days and the mood effect takes weeks. The receptor changes that lead to the actual mood improvement haven’t gotten anywhere yet. The asymmetry between when the side effects hit and when the benefits hit is the whole problem.
The guys who quit in week one are quitting because they got worse before they got better and nobody told them that was the normal arc. If your prescriber didn’t warn you about the first two weeks, your prescriber failed you, and it’s a kind of failure that was completely preventable with one extra sentence in the appointment. Which is not a great look for the profession.
Week two
This is the peak of side effects… nausea is at its worst, sleep is at its weirdest, the activating SSRIs (Lexapro, sertraline) sometimes give you a jittery, slightly anxious feeling that peaks in this window and that a lot of patients describe as the single hardest part of starting the drug. This is the week where you Google “is Lexapro making my anxiety worse” and you read a forum post from somebody who quit and you think about whether you should too.
You’ll also start noticing subtle shifts in sleep architecture and sometimes appetite. Some people sleep better, some sleep worse. Some people’s appetite is coming back to normal as a side effect of the depression itself loosening up. None of this is the mood effect yet. These are the autonomic shifts that come before the actual mood change, which is still weeks out.
Week three
Side effects start to ease, the nausea is mostly done, sleep is settling, the jittery feeling if you had it is fading. Your mood, in the average patient, is not noticeably better. This is the week where the highest dropout rate happens, because the side effects were bad and the benefit hasn’t appeared, and the reasonable conclusion looks like the drug isn’t working.
It is working. It’s just working on receptor changes that take longer than three weeks to show up as a felt mood shift… the experience of “this isn’t doing anything” is real and also incorrect, the receptor changes are happening, they just haven’t reached the level where you can feel them yet. If we’re being honest, this is the week where the whole project is most likely to get abandoned for the most preventable reason, which is a timeline expectation nobody set correctly at the start.
Weeks four through six
This is where mood usually starts to lift in people who are going to respond. Subtle at first. The mornings are slightly less heavy. The thoughts that used to spiral don’t spiral quite as long. Sleep feels more restorative. You catch yourself enjoying a moment that previously would’ve just been another moment. The change is usually not dramatic, it’s incremental, and a lot of patients don’t recognize it as the drug working because the change is gradual enough that you almost miss it from the inside.
The people in your life sometimes notice before you do. Wives in particular often pick it up a week or two before the patient does, because they’re not the one inside the head where the change is happening, they’re seeing the outside view of you being more like yourself. If your wife tells you you seem better and you don’t feel particularly better yet, believe her, she’s not lying and she’s not being optimistic, she’s looking at a face that’s started doing facial expressions again.
Weeks six through eight
Most of the antidepressant effect is online in people who are responding well. The lift is more obvious, more consistent. The dose may need a small bump up if the response is partial. The side effects that are going to stick around (sexual side effects mostly) have either declared themselves by now or they aren’t going to.
The clinical decision point at eight weeks is whether to push the dose, add a second drug, switch to a different class, or stay the course, which depends on the degree of response. Full responders stay where they are, partial responders augment or push the dose, non-responders at a real dose switch to something else.
Weeks eight through twelve
Full effect in patients who respond is usually here, mood is steady, energy is reasonable, sleep is actually restorative instead of just long. Sexual side effects, if they’re going to be a problem long-term, are clearly a problem by now and we can do something about them (add Wellbutrin, switch agents, whatever fits).
Patients who need a higher dose usually need it dialed in by week ten. Patients who need an augmenting agent usually start it around week ten if they haven’t fully responded to monotherapy. By week twelve the picture is mostly clear about whether the drug is going to work for you at this dose.
The “real dose” thing nobody mentions
Most patients who don’t respond to an antidepressant in eight weeks weren’t actually on a real therapeutic dose. The starting dose (10 mg Lexapro, 50 mg sertraline, 20 mg Prozac, 150 mg Wellbutrin XL) is exactly that, a starting dose, the place where you ramp up from, not where you stop. The therapeutic dose is typically double or triple the starting dose for full effect, and a lot of patients get told “the antidepressant didn’t work” when in fact they were never pushed past the floor.
A lot of guys whose prior antidepressant trials get called failures were on inadequate doses… they stopped at the starting dose, decided it wasn’t working after six weeks, and switched to something else. The right move was usually to push the dose first and see whether response emerged at the therapeutic dose before switching. Most people who think a drug failed them were sitting at a dose that was never the actual treatment.
What “working” actually looks like
It’s not a chemically uplifted feeling. The drug doesn’t add positive feeling on top of where you were. It takes off whatever was suppressing your normal range. People who respond well describe being themselves again, not being a different person. The depression lifting is more like fog clearing than like a euphoric boost. If you’re chasing a feeling of being chemically high, antidepressants are the wrong drug for that, you’re thinking of stimulants or something illegal.
The other thing “working” looks like is the people around you noticing it. Wives, friends, kids, coworkers. The mood shift becomes visible from the outside before it always feels clearly different from the inside, because depression itself comes with a self-perception distortion that makes it hard to tell whether you’re better. The external feedback is a more reliable gauge than your own internal monologue for the first few months, which is one of those clinical facts that’s true and that no patient ever wants to hear.
What’s nice to hear about all this
The thing nobody opens with, because we’ve all been trained to lead with risk and side effects, is that the people who do make it past week three and stay on a real dose for the full timeline mostly do get better. The path is bumpy. The destination is usually back to yourself. People come back at month four after eighteen months of feeling like garbage and describe being able to enjoy their kid’s birthday party for the first time since they can remember, or noticing the weather, or not white-knuckling Monday morning. That’s a real outcome. It’s worth saying out loud, because the post-it-note version of antidepressant content on the internet has gotten so risk-focused it has stopped mentioning that for most people who finish a trial, the trial works.
The pattern that finishes the timeline
Picture a guy who ends up coming out the other end of a successful antidepressant trial: somebody who got the timeline up front, white-knuckled week two, didn’t quit at week three when nothing seemed to be happening, started noticing small things at week four through six (sleep was better, the texts he’d been ignoring got answered), got more obviously better around weeks six through eight when his wife told him over breakfast that he seemed more like himself which surprised him because he didn’t think anything had changed yet, and had two genuinely good days back to back at week eight which was the first time he’d had that in a year. Around week ten the prescriber pushed the dose because the response was solid but partial, and by week sixteen he was in remission. Four months from start to feeling like himself. Three years later he’s still on it. The thing that kept him on it through week three was a single conversation in week one where somebody set the timeline correctly, which is most of the job of starting somebody on an antidepressant honestly.
Most patients have been told the drug failed when actually the dose failed.
What to actually do
Know what week two is going to feel like, which is the worst, and plan for it. Don’t make any conclusions at week three or four, the drug is doing stuff you can’t feel yet. If at week eight there’s been no response at a starting dose, don’t conclude the drug failed, push to the therapeutic range and give it another four to six weeks at the higher dose before concluding anything. If at week twelve at a real dose there’s still nothing, then yes, the drug isn’t working, and the next move is to switch, augment, or revisit the diagnosis (which often turns out to be the move that actually mattered, the diagnosis was bipolar II or untreated sleep apnea or alcohol-driven depression all along).
Tell your wife or whoever you live with what to look for and ask them to tell you what they see. The external view is more reliable than your view of yourself for the first few months, which is annoying but true.
Bottom line
Eight to twelve weeks at a real dose, and the path is not a straight line. Worst at week two, possibly noticeable at four to six, mostly there by eight to twelve in people who respond. Quitting at week three is the single most common avoidable reason antidepressant trials fail, and the reason it keeps happening is that nobody is telling patients what week three is going to feel like before they start. Now you know. That’s the whole post.
Sources
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PMID 17074942.
- Olgiati P, Serretti A, Souery D, et al. Early improvement and response to antidepressant medications in adults with major depressive disorder: Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord. 2018;227:777-786. PMID 29254066.
- Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609. PMID 31178367.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. PMID 29477251.
